Subtopic Deep Dive

Overactive Bladder Syndrome
Research Guide

What is Overactive Bladder Syndrome?

Overactive Bladder Syndrome (OAB) is a urological condition characterized by urinary urgency, with or without incontinence, usually accompanied by frequency and nocturia, investigated through antimuscarinic drugs, beta-3 agonists, and neuromodulation therapies.

OAB affects millions worldwide, with clinical trials evaluating symptom severity using indices like the Overactive Bladder Questionnaire. Research spans muscarinic receptor pharmacology and neural control of the lower urinary tract. Over 2,500 papers exist on OAB pathophysiology and treatments, including 627-cited Abrams et al. (2006) on muscarinic receptors.

15
Curated Papers
3
Key Challenges

Why It Matters

OAB management reduces healthcare costs and improves quality of life for 16% of adults over 40. Antimuscarinics block detrusor muscarinic receptors, as detailed in Abrams et al. (2006, 627 citations). Ouslander (2004, 410 citations) highlights distress from urgency incontinence, while Peyronnet et al. (2019, 398 citations) advocate tailored treatments to lower morbidity from falls and infections.

Key Research Challenges

Side Effects of Antimuscarinics

Antimuscarinic drugs cause dry mouth and cognitive impairment, limiting adherence. Abrams et al. (2006) note blockade of central muscarinic receptors contributes. Developing subtype-selective agents remains unresolved.

Heterogeneous Pathophysiology

OAB arises from detrusor overactivity, urothelial dysfunction, and neurologic factors. De Groat (2006, 400 citations) describes integrative LUT control challenges. Peyronnet et al. (2019) call for personalized diagnosis.

Limited Neuromodulation Access

Sacral neuromodulation efficacy varies by patient selection. Andersson and Wein (2004, 474 citations) outline pharmacologic gaps neuromodulation addresses. Scalability and long-term outcomes lack large trials.

Essential Papers

1.

Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder

Paul Abrams, Karl‐Erik Andersson, Jerry J. Buccafusco et al. · 2006 · British Journal of Pharmacology · 627 citations

The effectiveness of antimuscarinic agents in the treatment of the overactive bladder (OAB) syndrome is thought to arise through blockade of bladder muscarinic receptors located on detrusor smooth ...

2.

Pharmacology of the Lower Urinary Tract: Basis for Current and Future Treatments of Urinary Incontinence

Karl‐Erik Andersson, Alan J. Wein · 2004 · Pharmacological Reviews · 474 citations

3.

Management of Overactive Bladder

Joseph G. Ouslander · 2004 · New England Journal of Medicine · 410 citations

Symptoms of overactive bladder are common, are often distressing, and may have serious adverse consequences. Myriad factors — disorders of the lower urinary tract, neurologic conditions, behavioral...

4.

Integrative control of the lower urinary tract: preclinical perspective

William C. de Groat · 2006 · British Journal of Pharmacology · 400 citations

Storage and periodic expulsion of urine is regulated by a neural control system in the brain and spinal cord that coordinates the reciprocal activity of two functional units in the lower urinary tr...

5.

A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment

B. Peyronnet, Emma Mironska, Christopher R. Chapple et al. · 2019 · European Urology · 398 citations

6.

Interstitial cystitis: The great imposter! Epidemiology, etiology, diagnosis and management

Jack Barkin · 2003 · Journal of Sexual & Reproductive Medicine · 373 citations

About 115 years ago, the first diagnosis of interstitial cystitis (IC) was offered as a reason to explain the pain related to scarring and inflammation in the bladder.Later, Hunner described the pa...

7.

Host–pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic<i>Escherichia coli</i>bladder infection

Thomas J. Hannan, Makrina Totsika, Kylie J Mansfield et al. · 2012 · FEMS Microbiology Reviews · 339 citations

Bladder infections affect millions of people yearly, and recurrent symptomatic infections (cystitis) are very common. The rapid increase in infections caused by multidrug-resistant uropathogens thr...

Reading Guide

Foundational Papers

Start with Abrams et al. (2006, 627 citations) for muscarinic mechanisms in OAB treatment, then Andersson and Wein (2004, 474 citations) for LUT pharmacology basis, and Ouslander (2004, 410 citations) for clinical management.

Recent Advances

Peyronnet et al. (2019, 398 citations) reviews tailored pathophysiology; Karstens et al. (2016, 268 citations) examines urinary microbiome in UUI severity.

Core Methods

Electron microscopy for detrusor structure (Elbadawi et al., 1993); symptom indices like OAB-q; preclinical neural models (de Groat, 2006).

How PapersFlow Helps You Research Overactive Bladder Syndrome

Discover & Search

Research Agent uses searchPapers for 'overactive bladder antimuscarinics' to retrieve Abrams et al. (2006), then citationGraph reveals 627 citing papers on receptor subtypes, and findSimilarPapers uncovers Andersson and Wein (2004) for LUT pharmacology.

Analyze & Verify

Analysis Agent applies readPaperContent to Abrams et al. (2006) abstract for muscarinic distribution, verifyResponse with CoVe checks claims against Ouslander (2004), and runPythonAnalysis statistically verifies symptom index correlations from trial data using pandas.

Synthesize & Write

Synthesis Agent detects gaps in antimuscarinic adherence via contradiction flagging across Peyronnet et al. (2019) and Ouslander (2004); Writing Agent uses latexEditText for review drafting, latexSyncCitations for Abrams et al. (2006), and exportMermaid for LUT neural pathway diagrams.

Use Cases

"Analyze OAB microbiome correlation with urgency severity from Karstens et al."

Analysis Agent → readPaperContent on Karstens et al. (2016) → runPythonAnalysis (pandas on microbiome abundance vs. UUI scores) → statistical p-values and matplotlib plots output.

"Draft LaTeX review on OAB antimuscarinic evolution."

Synthesis Agent → gap detection across Abrams et al. (2006) and Peyronnet et al. (2019) → Writing Agent → latexEditText + latexSyncCitations + latexCompile → compiled PDF with figures.

"Find code for OAB detrusor contractility simulations."

Research Agent → paperExtractUrls from Elbadawi et al. (1993) → paperFindGithubRepo → githubRepoInspect → runnable Python models of aging detrusor biomechanics.

Automated Workflows

Deep Research workflow scans 50+ OAB papers via searchPapers, structures antimuscarinic efficacy report with GRADE grading. DeepScan applies 7-step CoVe to verify neuromodulation claims from de Groat (2006). Theorizer generates hypotheses on microbiome-OAB links from Karstens et al. (2016).

Frequently Asked Questions

What defines Overactive Bladder Syndrome?

OAB features urgency with or without incontinence, frequency, and nocturia, excluding other pathologies. Abrams et al. (2006) link it to detrusor muscarinic receptor overactivity.

What are primary OAB treatment methods?

Antimuscarinics block M3 receptors; beta-3 agonists relax detrusor. Andersson and Wein (2004) review pharmacology; Ouslander (2004) covers management strategies.

What are key papers on OAB?

Abrams et al. (2006, 627 citations) on muscarinics; Peyronnet et al. (2019, 398 citations) on pathophysiology; de Groat (2006, 400 citations) on neural control.

What open problems exist in OAB research?

Tailored therapies for heterogeneous causes; microbiome roles per Karstens et al. (2016); long-term neuromodulation outcomes lack data.

Research Urinary Bladder and Prostate Research with AI

PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:

See how researchers in Health & Medicine use PapersFlow

Field-specific workflows, example queries, and use cases.

Health & Medicine Guide

Start Researching Overactive Bladder Syndrome with AI

Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.

See how PapersFlow works for Medicine researchers